US Stem Cell Inc (USRM)

[TheHungryHippo]

STEM CELL ACQUISITIONS IN BIG PHARMA

YEA! PHASE 2/3 MARVEL TRIALS ARE 100% FDA APPROVED

They have spend over 100 million dollars in research this far to get MYOCELL into phase2/3.

There is hardly ANY Stem Cell companies out there that have studies that have passed phase 3.

You know why? Because THE FDA hasn't hardly approved Stem Cell Therapies for commercial use yet. only a select handful. .Im talking maybe one or two. But now that the 21st century Cures act has been passed by congress this is all about to change.

Recent Acquisitions made by BIG PHARMA that show a Stem Cell Therapy company does not need to complete their trials in order to be captured by a larger company for a LARGE amount!

Big Pharma would rather take it to the finish line themselves. YEAH FOLKS.
In this case YOU DONT FOLLOW THE MONEY THE MONEY FOLLOWS YOU!

NeoStem to Acquire CSC in Potential $124M-Plus Stem Cell Deal
NeoStem said today it will acquire California Stem Cell (CSC) in a stock-and-cash deal that could total more than $124 million and will add a late-stage technology to the acquiring company’s pipeline. Through the deal, NeoStem will take over development of CSC’s Melapuldencel-T, an autologous melanoma initiating (stem) cell immune-based therapy intended to eliminate the tumor cells capable of causing disease recurrence, beginning with the launch of a pivotal Phase III trial.

http://www.genengnews.com/gen-news-highlights/neostem-to-acquire-csc-in-potential-124m-plus-stem-cell-deal/81249742

Cellular Dynamics International, an up-and-coming player in the stem cell field and one of Wisconsin’s more promising biotech companies, is being acquired by Fujifilm for $307 million in cash

http://www.xconomy.com/wisconsin/2015/03/30/fujifilm-snaps-up-cellular-dynamics-to-grow-stem-cell-business/


Cancer and inflammatory therapeutics developer Celgene has acquired privately held Anthrogenesis (placental stem cell technology) in a stock swap valued at approximately $45mm. The company will become a wholly owned subsidiary of Celgene


With $379M Deal For Ocata, Astellas Buys Stem Cells For Eye Diseases

http://www.xconomy.com/boston/2015/11/10/with-379m-deal-for-ocata-astellas-buys-stem-cells-for-eye-diseases/#

AMAG Acquires Top Stem Cell Company
Jun 29, 2015
By Pharmaceutical Executive Editors

AMAG Pharmaceuticals (Waltham, MA) is to acquire Cord Blood Registry (CBR; San Bruno, CA) for $700 million. Founded in 1992, CBR is the world’s largest newborn stem cell company; according to AMAG's press release, its acquisition of CBR will "expand AMAG's suite of maternal health offerings and add a high-margin business with complementary commercial capabilities and attractive future growth opportunities to [its] portfolio".

http://www.prnewswire.com/news-releases/mallinckrodt-to-acquire-stratatech-corporation-a-regenerative-medicine-company-focused-on-proprietary-therapeutic-human-skin-substitute-products-300312129.html
http://www.pharmexec.com/amag-acquires-top-stem-cell-company

Stemcentrx, a startup with backing from Silicon Valley investors including Artis Ventures and Founders Fund, was just acquired by AbbVie for $5.8 billion in cash and stock.

http://www.businessinsider.com/stemcentrx-acquired-by-abbvie-2016-4

http://www.prnewswire.com/news-releases/mallinckrodt-to-acquire-stratatech-corporation-a-regenerative-medicine-company-focused-on-proprietary-therapeutic-human-skin-substitute-products-300312129.html

Allergan has acquired regenerative medicine company LifeCell for $2.9 billion in cash, the company said Tuesday. The deal is expected to close early next year.

Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced that it has entered into a merger agreement with Stratatech Corporation, a privately held regenerative medicine company

http://www.bioforward.org/mallinckrodt-to-acquire-stratatech-corporation-a-regenerative-medicine-company-focused-on-proprietary-therapeutic-human-skin-substitute-products/

TiGenix Merges with Cellerix in $79.7M All-Share Deal
BioWorld International Correspondent

LONDON – TiGenix NV is merging with fellow cell therapy specialist Cellerix SA in an all-share deal valuing Cellerix at €58 million (US$79.7 million), creating a clear leader in the European regenerative medicine field, with two marketed products and a number of allogeneic adult stem cell therapies in clinical development.

THE LIST GOES ON AND ON FELLAS.

THE EVIDENCE IS CLEAR. BIG PHARMA ACTIVELY ON THE HUNT FOR STEM CELL THERAPIES.

YOU DONT NEED TO BE "FULLY FUNDED" TO GET SNATCHED UP BY BIG PHARMA.

ALL YOU NEED IS POSITIVE DATA. AND THAT IS SOMETHING THAT USRM HAS ALOT OF!



CSO Kristin Comella Publishes Paper on the Implantation of Stromal Vascular Fraction in Patients with Degenerative Disc Disease
https://finance.yahoo.com/news/cso-kristin-comella-publishes-paper-173400284.html